

# <u>Pharmacoepigenetics</u>: an element of personalized therapy?



# **RNA non codificante**

Non-coding RNA is an RNA that functions without being translated to a protein.





# micro-RNA



Cancer Gene Therapy (2008) 15, 341-355



# **Nomenclature of microRNA**



- According to standard nomenclature system, name of any MicroRNA is written as mir-123.
- miR = MicroRNA (mature form).
- mir = Precursor MicroRNA.
- Number indicates order of discovery.
- Annotated with an additional lower case letter e.g.miR-123a & miR-123b, if deference in only one or two nucleotides.



# microRNA detection methods



- qRT-PCR;
- TaqMan miRNA array;
- Microarray;
- NGS.



# microRNA database http://www.mirbase.org/

← → C @ O A https://www.mirba	ise.org						☆	Q mirbase			$\rightarrow$	9	) <u>*</u>	) IIIV	▣ ≡
miRBase			m	niRB	ase								M	ANCH	IESTER 1824
Home Search Browse Help Download Blog S	iubmit .														submit
miRBase: the microRNA databa	se									miRNA Release	<b>count</b> : <u>22.1</u>	: 38589 e	ntrie	s	
miRBase provides the following services:										Search	n by mil	RNA nam	e or l	keyw	ord
<ul> <li>The <u>miRBase database</u> is a searchable database database represents a predicted hairpin portion and sequence of the mature miRNA sequence (in <u>browsing</u>, and entries can also be retrieved by revealable for <u>download</u>.</li> <li>The <u>miRBase Registry</u> provides miRNA gene hur <u>help pages</u> for more information about the name</li> </ul>	e of published miRN of a miRNA transc termed miR). Both name, keyword, ref nters with unique n ing service.	IA sequer ipt (term hairpin a erences a ames for	nces an led mir nd matu and ann novel r	d annot in the d ure sequ notation. miRNA g	ation. E atabase Jences All sec Jenes p	Each er e), with are ava quence rior to	try in the informa iilable for and anno publicatio	e miRBase Seq tion on the loc r <u>searching</u> and otation data ar on of results. V	juence cation d re also /isit the	Downlo Downlo	oad pul bad page	Go blished m	Exar	nple	a
To receive email notification of data updates and feat directed at <u>mirbase@manchester.ac.uk</u> .	ure changes please	subscrib	e to the	e <u>miRBa</u>	se ann	ouncer	nents ma	<u>iling list</u> . Any q	queries a	bout the v	website (	or naming	servi	ce sho	ould be
miRBase is managed by the <u>Griffiths-Jones lab</u> at the supported by the <u>Wellcome Trust Sanger Institute</u> .	Faculty of Biology,	Medicine	and He	<u>ealth, Ur</u>	<u>niversit</u>	y of Ma	nchester	with funding f	from the	BBSRC. n	niRBase	was previo	ously	hoste	d and
References															
If you make use of the data presented here, pl miRBase: from microRNA sequences to function. Kozomara A, Birgaoanu M, Griffiths-Jones S.	ease cite the fol	owing a	rticles	in add	ition t	o the	orimary	data sources	5:						,
Scrivi qui per eseguire la ricerca	O 🛱 🧲	1 0	-	~	0	۲						^ @ ₩ /	信 (1))	11:2 10/12/	2021



# microRNA database http://www.mirbase.org/

miRBase		miRBase		MANCHESTER 1824
Home Search Browse Help Download Bl	og Submit Search	results		hsa-miR-331-3p Search
Search Results We found 1 unique result for your query ("hsa	<i>-miR-331-3p</i> "), in <b>1</b> se	ction of the database.		
	Section	Description	Number of hits	
	miRNA name	match the accession or ID of a hairpin precursor entry	0	
	Previous ID	match the previous ID of a hairpin precursor entry	0	
	Mature name	match the accession or ID of a mature miRNA sequence	1	
	Previous Mature ID	match the previous mature ID of a mature entry	0	
	Dead entry	match the accession or ID of a dead entry	0	
	Dead entry previous ID	match the accession or ID of a dead entry	0	
	Gene symbol	find miRNA entries based on gene symbols	0	
	Description	search miRNA entry description	0	
	Comments	search miRNA entry comments	0	
	PubMed ID	find miRNA entries based on literature reference PubMed ID	0	
	Literature reference	search title and authors of associated literature references	0	
The above key shows a brief description of ea below. Click the column headings to sort the r	ach of the database se esults table, or <u>restore</u>	ctions, along with the number of hits found in each one to the original order.	. Only unique miR	NA entries are shown in the results table
		Accession∰ ID∰ Mature name∰ /IIMAT0000760 hsa-miR-331-3p ✓		

Comments, questions? Email mirbase@manchester.ac.uk



# microRNA database http://www.mirbase.org/

miRBase				miRE	Base			MANCHESTER
Home Search Br	owse Help	Download Blog	Submit					Search
Mature seque	nce hsa-	miR-331-3p						
Accession number	MIMAT0000	760						
ID	hsa-miR-33	1-3p						
Previous IDs	hsa-miR-33	1						
Stem-Loop	hsa-mir-331							
Sequence	gacaauggga Get sequend	cuauccuagaa e						
Deep sequencing	<u>118219</u> rea	ds, 152 experiments						
Database links	RNAcentral	URS00003DDE27 9	<u>606</u>					
Predicted targets	TargetMiner TargetScan miRDB: <u>hsa</u> microrna.or	:: <u>hsa-miR-331-3p</u> Vert: <u>hsa-miR-331-3p</u> <u>i-miR-331-3p</u> g: <u>hsa-miR-331-3p</u>	2					
QuickGO	Qualifier	GO term	Evidence	Notes	Reference			
Tunction	part_of	<u>GO:0005615</u>	ECO:0007005	undefined	PMID: 26646931			
		extracellular space	nign throughput direct assay evidence used in manual assertion	08ERON:0001969			[Records 1-1 of 1] [Qui	ickGO full record]
References								
1	PMID: <u>1469</u> <u>Identificati</u> Kim J, Kriche Proc Natl Ac	<u>1248</u> on of many microRNA evsky A, Grad Y, Hay ad Sci U S A, 101;360	s that copurify with polyribosomes in mammalian neurons" es GD, Kosik KS, Church GM, Ruvkun G D-365(2004).					
2	PMID: 1563 New human Weber MJ	1332 n and mouse microRN	A genes found by homology search*					



# microRNA database http://mirdb.org/

$\langle \rangle$	mird	3
<u>Target Search</u> <u>Target Mining</u> <u>Custom Prediction</u>	Choose one of the following search options: Search by miRNA name Human V Go Clear	
FuncMir Collection Data Download Statistics	Search by gene target Human v Gene Symbol v Go Clear	
<u>Help   FAQ</u> <u>Comments</u> <u>Citation   Policy</u>	miRDB is an online database for miRNA target prediction and fun- bioinformatics tool, MirTarget, which was developed by analyzing experiments. Common features associated with miRNA target bin machine learning methods. miRDB hosts predicted miRNA targets update, users may provide their own sequences for customized to and literature mining, functionally active miRNAs in humans and annotations, are presented in the FuncMir Collection in miRDB.	tional annotations. All the targets in miRDB were predicted by a thousands of miRNA-target interactions from high-throughput sequencing ding have been identified and used to predict miRNA targets with in five species: human, mouse, rat, dog and chicken. As a recent rget prediction. In addition, through combined computational analyses nice were identified. These miRNAs, as well as associated functional

#### References:

- Nathan Wong and Xiaowei Wang (2015) miRDB: an online resource for microRNA target prediction and functional annotations. <u>Nucleic Acids Research</u>. 43(D1):D146-152.
- Xiaowei Wang (2016) Improving microRNA target prediction by modeling with unambiguously identified microRNA-target pairs from CLIP-Ligation studies. <u>Bioinformatics</u>. 32(9):1316-1322.



# microRNA database http://mirdb.org/

miRDB

#### There are 411 predicted targets for hsa-miR-331-3p in miRDB.

Target Detail	Target Rank	Target Score	miRNA Name	Gene Symbol	Gene Description
Details	1	99	hsa-miR-331-3p	NRP2	neuropilin 2
Details	2	96	hsa-miR-331-3p	PTPN2	protein tyrosine phosphatase, non-receptor type 2
Details	3	96	hsa-miR-331-3p	ZBTB2	zinc finger and BTB domain containing 2
Details	4	96	hsa-miR-331-3p	PHLPP1	PH domain and leucine rich repeat protein phosphatase 1
Details	5	94	hsa-miR-331-3p	CPSF2	cleavage and polyadenylation specific factor 2
Details	6	94	hsa-miR-331-3p	ZNF652	zinc finger protein 652
Details	7	93	hsa-miR-331-3p	DCLRE1B	DNA cross-link repair 1B
Details	8	93	hsa-miR-331-3p	TSPAN18	tetraspanin 18
Details	9	92	hsa-miR-331-3p	SLAMF9	SLAM family member 9
Details	10	92	hsa-miR-331-3p	SEMA7A	semaphorin 7A (John Milton Hagen blood group)
Details	11	92	hsa-miR-331-3p	BAIAP2	BAI1 associated protein 2
Details	12	91	hsa-miR-331-3p	CNTNAP4	contactin associated protein like 4
Details	13	90	hsa-miR-331-3p	FBLN7	fibulin 7
Details	14	90	hsa-miR-331-3p	CDC42EP4	CDC42 effector protein 4
Details	15	90	hsa-miR-331-3p	ARHGEF37	Rho guanine nucleotide exchange factor 37
Details	16	90	hsa-miR-331-3p	<u>XP07</u>	exportin 7
Details	17	88	hsa-miR-331-3p	DUSP5	dual specificity phosphatase 5
Details	18	88	hsa-miR-331-3p	APBA1	amyloid beta precursor protein binding family A member 1
Details	19	88	hsa-miR-331-3p	UBL3	ubiquitin like 3
Details	20	87	hsa-miR-331-3p	TGFBR1	transforming growth factor beta receptor 1
Details	21	87	hsa-miR-331-3p	ZMYM4	zinc finger MYM-type containing 4
Details	22	87	hsa-miR-331-3p	SARM1	sterile alpha and TIR motif containing 1
	O Scrivi	i qui per es	eguire la ricerca	C	) 🛱 🍯 🐂 💽 💁 💼 📵



# microRNA database

# http://mirtarbase.mbc.nctu.edu.tw/php/index.php

				Jearch			
niRTarBase	# Home	Search	Browse	Statistics	Help	Download	Contact I
niRTarBase: the experimentally valio atabase	dated microRNA	A-target	interac	tions	Curren	t curatior 0: Sept. 15, 20'	<b>1</b>
s a database, miRTarBase has accumulated more than t teractions (MTIs), which are collected by manually surve rstematically to filter research articles related to function	three hundred and sixty t eying pertinent literature nal studies of miRNAs. G	housand mil after NLP of Generally, the	RNA-target the text collected N	ITIs are	Number of	f articles: 8,510	
ilidated experimentally by reporter assay, western blot, r operiments. While containing the largest amount of valid	nicroarray and next-gene lated MTIs, the miRTarBa	eration seque ase provides	the most u	pdated	Number of	f species: 23	
ellection by comparing with other similar, previously deve	eloped databases.						
ollection by comparing with other similar, previously deve Major improvments	eloped databases.				Number of	f target genes:	23,054
ollection by comparing with other similar, previously deve Major improvments	eloped databases.	miRTarBas	e 7.0		Number of Number of	f target genes: f miRNAs: 4,07	23,054 6
Allection by comparing with other similar, previously deve Major improvments Features Release date	eloped databases. miRTarBase 6.0 2015/09/15	miRTarBas	e 7.0	1	Number of Number of	f target genes: f miRNAs: 4,07 f miRNA-target	23,054 6
Allection by comparing with other similar, previously deve Major improvments Features Release date Known miRNA entry	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20	miRTarBas 2017/09/ miRBase v	e 7.0 /15 v21		Number of Number of Number of	f target genes: f miRNAs: 4,07 f miRNA-target	23,054 6 Interactions
Allection by comparing with other similar, previously deve Major improvments Features Release date Known miRNA entry Known Gene entry	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20 Entrez 2015	miRTarBas 2017/09/ miRBase Entrez 20	e 7.0 /15 v21		Number of Number of Number of 422,517	f target genes: f miRNAs: 4,07 f miRNA-target	23,054 6 Interaction:
Allection by comparing with other similar, previously deve Major improvments Features Release date Known miRNA entry Known Gene entry Species	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20 Entrez 2015 18	miRTarBas 2017/09/ miRBase Entrez 20	e 7.0 /15 v21 017 23		Number of Number of Number of 422,517	f target genes: f miRNAs: 4,07 f miRNA-target	23,054 6 Interaction:
Allection by comparing with other similar, previously deve Alajor improvments Features Release date Known miRNA entry Known Gene entry Species Curated articles	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20 Entrez 2015 18 4,966	miRTarBas 2017/09/ miRBase Entrez 20	e 7.0 (15 v21 017 23 8,510		Number of Number of Number of 422,517	f target genes: f miRNAs: 4,07 f miRNA-target	23,054 6 Interaction:
Allection by comparing with other similar, previously deve Major improvments Features Release date Known miRNA entry Known Gene entry Species Curated articles miRNAs	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20 Entrez 2015 18 4,966 3,786	miRTarBas 2017/09/ miRBase v Entrez 20	e 7.0 (15 v21 017 23 8,510 4,076		Number of Number of Number of 422,517	f target genes: f miRNAs: 4,07 f miRNA-target	23,054 6 Interaction
Alection by comparing with other similar, previously deve Major improvments Features Release date Known miRNA entry Known Gene entry Species Curated articles miRNAs Target genes	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20 Entrez 2015 18 4,966 3,786 22,563	miRTarBas 2017/09/ miRBase Entrez 20	e 7.0 (15 v21 117 23 8,510 4,076 23,054		Number of Number of Aumber of 422,517	f target genes: f miRNAs: 4,07 f miRNA-target <b>RNA resou</b>	23,054 6 Interactions
Aliection by comparing with other similar, previously deve Alajor improvments Features Release date Known miRNA entry Known Gene entry Species Curated articles miRNAs Target genes CLIP-seq datasets	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20 Entrez 2015 18 4,966 3,786 22,563 138	miRTarBas 2017/09/ miRBase Entrez 20	e 7.0 (15 v21 )17 23 8,510 4,076 23,054 231		Number of Number of Aumber of 422,517 MicroF from IS	f target genes: f miRNAs: 4,07 f miRNA-target RNA resou	23,054 6 Interaction: JICES
Allection by comparing with other similar, previously deve Alajor improvments Features Release date Known miRNA entry Known Gene entry Species Curated articles miRNAs Target genes CLIP-seq datasets Curated miRNA-target interactions	eloped databases. miRTarBase 6.0 2015/09/15 miRBase v20 Entrez 2015 18 4,966 3,786 22,563 138 366,181	miRTarBas 2017/09/ miRBase Entrez 20	e 7.0 (15 v21 017 23 8,510 4,076 23,054 231 422,517		Number of Number of 422,517 MicroF from IS	f target genes: f miRNAs: 4,07 f miRNA-target RNA resou	23,054 6 Interaction: JICES



# microRNA database http://mirtarbase.mbc.nctu.edu.tw/php/index.php

By miRNA       By Target Gene       By Pathway       By Validated Method       By Disease       By Literature         Advanced Search       Search miRTarBase       Image: Comparison of the search option       Image: Comparison of the search op	RTarBas	e		Home Q Search	Browse	Statistics	Help	Download	Contac
Species:   Please select  Select one search option  (a) miRNA ID:  (b) miRNA Family:	By miRNA Advanced S	By Target Gene	By Pathway	By Validated Method	By Disease	By Literature			
Select one search option       O (a) miRNA ID: •       O (b) miRNA Family: •	Search	n miRTarBase	lest					-	
O (a) mIRNA ID: - O (b) mIRNA Family: -	Species:	one search option	e select					_	
	Select c	inere lar							



### microRNA database

# http://mirtarbase.mbc.nctu.edu.tw/php/index.php

miR1	<b>TarBa</b>	se		Home	e Search	Br	owse	St	atisti	cs	Help	Do	own	load	Contact Us
	Page of 15	Prev 1 2	15 Next >						P a	ulse cids	d sta in ce	ble i ll cu	sot Itur	ope re (p	labeling by am SILAC)
							V	alidat	ion m	etho	is				
						e	Stron viden	g ce		Less evid	stron ence	9			
	ID	Species (miRNA)	Species (Target)	miRNA	Target	Reporter assay	Western blot	qPCR	Microarray	NGS	pSILAC	Other	Sum	# of papers	
	MIRT002222	Rattus norvegicus	Rattus norvegicus	mo- miR-331-3p	Fgf16				~			•	2	1	
	MIRT005805	Homo sapiens	Homo sapiens	hsa- miR-331-3p	ERB82	•	•	~	~			•	5	5	
	MIRT006364	Homo sapiens	Homo sapiens	hsa- miR-331-3p	FHIT	•							Ŧ	1	
	MIRT006506	Homo sapiens	Homo sapiens	hsa- miR-331-3p	E2F1	•	•						2	٦.	
	MIRT006887	Homo sapiena	Homo sapiens	hsə- miR-331-3p	DOHH	•	•	-		~			4	2	
	MIRT019230	Homo sapiens	Homo sapiens	hsa- miR-331-3p	WDR60					•			ĩ	Ť	
	MIRT019231	Homo sapiens	Homo sapiens	hsa- miR-331-3p	RNF7					-			1	1	
	MIRT019232	Homo sapiens	Homo sapiens	hsa- miR-331-3p	ARLSA					-			Ŧ	1	
	MOTOLOGIC	the second second	1	12.2	THOPPO										

# MicroRNAs in the Control of Drug Metabolism and Transport

2r

		MicroRNA	Reference
Enzymes	CYP1B1	miR-27b	Tsuchiya et al., 2006
	CYP2E1	miR-378	Mohri et al., 2010
	CYP3A4	miR-27b, mmu-miR-298	Pan et al., 2009a
Transporters	ABCB1	miR-451	Kovalchuk et al., 2008
		miR-27a	Zhu et al., 2008
	ABCG2	miR-520h	Liao et al., 2008; Wang et al., 2010; Li et al., 2011
		miR-519c	To et al., 2008; To et al., 2009; Li et al., 2011
		miR-328	Pan et al., 2009b; Li et al., 2011
	ABCC1	miR-134	Guo et al., 2010
		miR-326	Liang et al., 2010
		miR-199a, miR-199b, miR-296	Borel et al., 2012
		miR-1291	Pan et al., 2013
	ABCC2	miR-379	Haenisch et al., 2011
	ABCC3	miR-9-3p	Jeon et al., 2011
	ABCC4	miR-125a, miR-125b	Borel et al., 2012
	ABCC5	miR-101, miR-125a, Let-7a	Borel et al., 2012
		miR-128	Zhu et al., 2011
	ABCC6	miR-9-3p	Jeon et al., 2011

Some P450 drug-metabolizing enzymes and ABC transporters shown to be targeted by noncoding miRNAs



# **Deregulated expression of microRNAs**



The mechanisms of deregulated expression of microRNAs. Different mechanisms can promote or/and inhibit the expression of miRNA

Si et al. Clinical Epigenetics (2019) 11:25 https://doi.org/10.1186/s13148-018-0587-8



# **Exosomes-derived microRNA and drug resistance**









# Circulating microRNA





# **RNA non codificante**

Non-coding RNA is an RNA that functions without being translated to a protein.





# circRNAs

- Covalently circularized RNA loops
- Stable in cells and long in half-lives
- Multiple miRNA binding sites as miRNA sponges



Nature Structural & Molecular Biology (2013), 20:5, 541-3



Nature (2013) 495, 333-343





#### **CircRNAs promote drug resistance**

#### **CircRNAs** inhibite drug resistance

Review Open Access Published: 05 August 2020

CircRNAs: biogenesis, functions, and role in drugresistant Tumours







# What is non-coding RNA?

Non-coding RNA is an RNA that functions without being translated to a protein.







**IncRNA** 

#### LncRNAs and drugs affecting their expression in cancers

LncRNA	Cancer	Drug	Cancer Stem Cells (C. Mechanism of Enithelial to mesonehymal transitions (El
11/21/1	BLU		drug resistance
UCAI	Bladder	2	LncRNA
Linc-ROR	Hepatocellular carcinoma	Sorafenib and doxorubicin	in cancer
XIST	Ovarian, breast	Cisplatin, abexinostat	CSC UCAI, AISI MALAT L line POP (miRN)
MALAT-1	Pancreas	Gemcitabine	MALAT-T, UNC-KOK
URHC	Hepatocellular carcinoma	PD98059	EMT MALAT-1 HOTTIP
HOTAIR	Lung	Cisplatin	
PCGEM1	Prostate	Doxorubicin	DNA repair Apoptosis URHC HOTAR PCCEM
GAS5	Lung	Gentinib	and $GAS5 \ AK126698 \ ERIC$
AK126698	Lung	Cisplatin	cell cycle autophagy PANDA, PDAM, HOTTIP
ERIC	Bone osteosarcoma	Etoposide	
PANDA	Breast	Doxorubicin	Drug
PDAM	Oligodendroglial	Cisplatîn	efflux
HOTTIP	Pancreas	Gemcitabine	
PRNA		Mitoxantrone	Drug MRUL
H19	Hepatocellular carcinoma cells	Paclitaxel, doxorubicin, etoposide, and vincristine	metabolism
MRUL	Gastric	Doxorubicin and vincristine	Mutation of PVT1 miRNA
ARA	Breast, hepatocellular carcinoma cells	Doxorubicin	drug targets
PVT1	Pancreas, gastric cancer	Gemcitabine, paclitaxel	mothylation H19
BCAR4	Breast	Tamoxifen	methylation

Urothelial Carcinoma-Associated 1 (UCA1)

Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT-1)



# **Pharmacoepigenetics of Glucocorticoids**







# **GLUCOCORTICOIDS**









# EPIGENETIC PREDICTORS OF GLUCOCORTICOID RESPONSE IN CHILDREN WITH IBD

The research project was supported by Italian Ministry of Health, No. 44/GR-2010-2300447





IRCCS materno infantile Burlo Garofolo



University of Padua CRIBI Genomics



## CANDIDATE PREDICTORS OF GLUCOCORTICOID RESPONSE IN CHILDREN WITH IBD



#### Article

### High-Throughput Sequencing of microRNAs in Glucocorticoid Sensitive Paediatric Inflammatory Bowel Disease Patients

Sara De Iudicibus <sup>1,†</sup>, Marianna Lucafò <sup>2,†</sup>, Nicola Vitulo <sup>3</sup>, Stefano Martelossi <sup>1</sup>, Rosanna Zimbello <sup>4</sup>, Fabio De Pascale <sup>4</sup>, Claudio Forcato <sup>4</sup>, Samuele Naviglio <sup>5</sup>, Alessia Di Silvestre <sup>5</sup>, Marco Gerdol <sup>6</sup>, Gabriele Stocco <sup>6</sup>, Giorgio Valle <sup>4</sup>, Alessandro Ventura <sup>1,2</sup>, Matteo Bramuzzo <sup>1,\*</sup> and Giuliana Decorti <sup>1,2</sup>

### T4 vs T0 Table 1. Differentially expressed miRNAs.

Upregulated miRNAs	FC	FDR Corrected P-Value	Downregulated miRNAs	FC	FDR Corrected <i>p</i> -Value
hsa-miR-451a * [13]	4.16	$1.66 \times 10^{-6}$			
hsa-miR-144-3p * [14,15]	4.44	$1.04 \times 10^{-5}$			
hsa-miR-96-5p * [13,14]	2.96	$6.38 \times 10^{-3}$			
hsa-miR-29b-3p * [13]	2.89	0.026			
hsa-miR-142-3p * [14]	2.21	0.026			
hsa-miR-873-5p	3.36	0.026			
hsa-miR-29c-3p * [16,17]	3.37	0.037			
hsa-miR-29a-3p * [13]	2.72	0.041	hsa-miR-7109-3p	-4.62	0.044
hsa-miR-363-3p	2.31	0.041	hsa-miR-654-5p	-2.27	0.049
hsa-miR-141-3p	2.59	0.041			
hsa-miR-548ak	3.11	0.042			
hsa-let-7g-3p* [18]	2.44	0.042			
hsa-miR-4772-5p	2.70	0.047			
hsa-miR-106a-3p	3.52	0.047			
hsa-miR-31-3p	3.36	0.049			
hsa-miR-146b-5p * [19]	2.27	0.049			

Fold changes (FC) for each miRNA regulated by glucocorticoids (GCs); \* Linked to GC regulation in the literature. FDR, False Discovery Rate.



### **IN CHILDREN WITH IBD**

Validation of Selected Differentially Expressed miRNAs by qRT-PCR



Figure 2. Relative expression of miR-451a, miR-144-3p, and miR-29c-3p (calculated as  $2^{-\Delta\Delta Ct}$  T4 vs. T0). Values > 1 (dotted line) indicate upregulation, values < 1 indicate downregulation. Parametric *t*-test  $\Delta C_t$  T0 vs. T4, \*\* *p* < 0.01.

miRNA	pGRE	Start	End	Strand	Chrom	Expression
hsa-miR-363	GTGATAATGTGTGCTT	133303695	133303710		chrX	Up
hsa-miR-96	AGGACAAAGAGTCCTC	129416083	129416098	22	chr7	Up
hsa-miR-142	CTCACCTTCAGTTCTG	58331606	58331621	+	Chr17	Up
hsa-miR-142	CTGTCAGTCTGTCCTC	58332656	58332671		Chr17	Up



## **CANDIDATE PREDICTORS OF GLUCOCORTICOID RESPONSE IN CHILDREN WITH IBD**

T0 PRvsPS							
UP	FC	DOWN	FC				
hsa-miR-1180-3p	7,96	hsa-miR-100-5p	43,95				
hsa-miR-3591-3p	11,2	hsa-miR-1227-5p	2093,27				
		hsa-miR-1255a	45,07				
		hsa-miR-1271-5p	17,98				
		hsa-miR-24-2-5p	15				
		hsa-miR-25-5p	19,44				
		hsa-miR-3065-5p	22,25				
		hsa-miR-31-3p	25,65				
		hsa-miR-3196	38,62				
		hsa-miR-3656	19,63				
		hsa-miR-3960	150,33				
		hsa-miR-4443	47,81				
		hsa-miR-4772-3p	20,55				
		hsa-miR-5586-3p	17,04				
		hsa-miR-6075	4465,59				
		hsa-miR-6087	25,93				
		hsa-miR-618	26,38				
		hsa-miR-876-5p	19,32				



#### OPEN MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF- $\kappa B$ signaling pathway Pereived-08 July 2015

Accepted: 03 February 2016 Published: 01 March 2016

Guosheng Tan<sup>1,\*</sup>, Linwei Wu<sup>2,\*</sup>, Jinfu Tan<sup>3</sup>, Bing Zhang<sup>4</sup>, William Chi-shing Tai<sup>5,6</sup>, Shiqiu Xiong<sup>7</sup>, Wei Chen<sup>1</sup>, Jianyong Yang<sup>1</sup> & Heping Li<sup>1,8</sup>

T4 PRvsPS						
UP	FC	DOWN	FC			
hsa-miR-1180-3p	6,48	hsa-miR-1197	10,19			
hsa-miR-4732-5p	5	hsa-miR-1227-5p 434,0				
		hsa-miR-154-3p	10,26			
		hsa-miR-4443	64,78			
		hsa-miR-4523	11,82			
		hsa-miR-6075	1561,21			
		hsa-miR-6087	20,31			
		hsa-miR-876-5p	25,93			





# **RESPONSE IN CHILDREN WITH IBD**

Clin Transl Gastroenterol. 2016 Sep 15;7(9):e192. doi: 10.1038/ctg.2016.49.

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease.

Prednisone

Down

Heier CR<sup>1</sup>, Fiorillo AA<sup>1</sup>, Chaisson E<sup>2</sup>, Gordish-Dressman H<sup>1,3</sup>, Hathout Y<sup>1,3</sup>, Damsker JM<sup>1,4</sup>, Hoffman EP<sup>1,3,4</sup>, Conklin LS<sup>1,2</sup>.

### Bioinformatic analysis of gene regulation pathways



miR-486

GR







**Fig. 1** Cells were exposed for 72 h to MP at 20  $\mu$ g/ml and/or different concentrations of RAPA, and cell proliferation was evaluated by MTT assay. Two-way ANOVA (P<0.0001) and Bonferroni post-test \*\*\* p-value<0.001.

Cancer Chemotherapy and Pharmacology (2020) 86:361-374 https://doi.org/10.1007/s00280-020-04122-z

**ORIGINAL ARTICLE** 

#### miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway

Marianna Lucafò<sup>1</sup> · Daria Sicari<sup>2,3</sup> · Andrea Chicco<sup>4</sup> · Debora Curci<sup>5</sup> · Arianna Bellazzo<sup>6</sup> · Alessia Di Silvestre<sup>5</sup> · Chiara Pegolo<sup>6</sup> · Robert Autry<sup>7</sup> · Erika Cecchin<sup>8</sup> · Sara De Iudicibus<sup>1</sup> · Licio Collavin<sup>6</sup> · William Evans<sup>7</sup> · Giuliana Decorti<sup>1,4</sup> · Gabriele Stocco<sup>6</sup>



Differentially expressed miRNAs.

The expression analysis identified 70, 99 and 96 miRNAs that were differentially expressed after treatment with MP, RAPA and MP+RAPA, respectively.



TaqMan® Array MicroRNA Cards

miRNA up e downregolati selettivamente dai diversi trattamenti farmacologici

	UP	DOWN
MP	hsa-miR-200b-3p	hsa-miR-181c-5p
		hsa-miR-192-5p
		hsa-miR-324-3p
		hsa-miR-361-5p
		hsa-miR-455-5p
		hsa-miR-576-3p
RAPA	hsa-miR-140-3p	hsa-miR-142-5p
	hsa-miR-26b-5p	hsa-miR-365a-3p
	hsa-miR-28-5p	hsa-miR-455-3p
	hsa-miR-324-5p	hsa-miR-501-5p
	hsa-miR-454-3p	
MP+RAPA	hsa-miR-30b-5p	hsa-miR-19a-3p
	hsa-miR-30c-5p	hsa-miR-886-3p
	hsa-miR-331-3p	hsa-miR-886-5p
	hsa-miR-345-5p	
	hsa-miR-744-5p	



**DIANA miRPath v.2.0**: investigating the combinatorial effect of microRNAs in pathways http://snf-515788.vm.okeanos.grnet.gr/





		C-12-27-6		Statistics - Adaption - Statistics					
	2	UPRE	GULAT	ED miRN	As				
Detterm	MP		RAPA			MP+RAPA			
Patnways	p-Value	Gene	miRNA	p-Value	Gene	miRNA	p-Value	Gene	miRNA
ECM-receptor interaction	5.067 e- 27	26	14	1.611 e- 27	30	20	1.674 e- 21	36	21
Biotin metabolism	7.131 e-5	2	2	0.0009	2	3	0.002	2	3
Vitamin B6 metabolism	0.00057	4	4	0.0294	3	3	0.0416	3	4
PI3K-Akt signaling pathway	0.00687	96	29	0.0009	124	44	0.0025	130	48
p53 signaling pathway	0.0086	24	18	0.0071	30	27	0.00271	33	31
Protein digestion and absorption	0.02	31	15	-	_	-	-	-	-
Ras signaling pathway	0.0201	64	26	0.003	85	39	0.027	83	42
Glycosaminoglycan biosynthesis	0.025	6	5	-		-	0.0065	11	11
Tight junction	0.028	41	21	-	-	-	-	-	-
Estrogen signaling pathway	0.0291	29	16	-	-	-	-	<u>-</u> 2	-
Neurotrophin signaling pathway	0.042	36	22	0.0294	47	31	0.0053	53	34
Fatty acid biosynthesis	-	-	-	1.898 e- 13	4	4	3.734 e- 12	4	5
Prion diseases	-	-	-	5.169	9	12	-	-	-
Bacterial invasion of epithelial cells	-		-	0.0052	34	28	-		-
Ubiquitin mediated proteolysis	_	-	-	0.0071	55	33	0.0146	57	37
MAPK signaling pathway	-	-	-	-	-	-	0.00576	98	41
Proteoglycans in cancer	0.019	74	39	-	-	-			-

DOWNREGULATED miRNAs									
Dathways	MP		RAPA			MP+RAPA			
Fuinways	p-Value	Gene	miRNA	p-Value	Gene	miRNA	p-Value	Gene	miRNA
Fatty acid biosynthesis	3.31 e-26	4	3	1.123 e- 23	3	2	7.532 e- 21	3	1
Fatty acid metabolism	2.069 e-8	11	9	0.00064	9	8	0.007	9	6
Proteoglycans in cancer	3.569 e-5	40	16	0.00074	37	20	0.0019	35	15
Thyroid hormone signaling pathway	0.0015	20	15	-	-	_	-	-	-
Path regulat pluripot of stem cells	0.005	30	15	0.03099	30	20	-	_	<u>-</u>
Thyroid hormone synthesis	0.0075	12	8	-	-	_	-	-	_ *
Glycosphingolipid biosynthesis	0.0106	5	3	0.0248	6	7	-	-	_3
N-Glycan biosynthesis	0.0314	10	9	0.0248	12	9	0.03	10	8
PI3K-Akt signaling pathway		-	-	0.0248	67	22	-	-	-3
Acute myeloid leukemia	-	-	-	0.0309	15	14	-	-	
ErbB signaling pathway	-	-	100	-	-	-	0.014	22	14

miR-331-3p

DIFFERENTIAL EXPRESSION OF miRNAs IN RAPAMYCIN-INDUCED



Nature Reviews | Cancer





GC resistance reversion by RAPA through suppression of the JNK protein



miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway

reported as means ± SE of three

independent experiments



Fig. 7 Expression level of miR-331-3p in leukemia cells derived from patients sensitive or resistant to GCs. Linear model \*p<0.05



# **Growth arrest-specific 5 (GAS5)**





# **ROLE OF GAS5 IN GC RESPONSE**

Samples from blood donors



Pharmacodynamic test: inhibition of in vitro proliferation by the test of incorporation of [<sup>3</sup>H]-thymidine.





Lucafò M. et al., Curr Mol Med 2015



Spearman rho= -0,73; P value= 0.0009

Lucafò M. et al., Clin and Exp Pharm and Phys 2016





# **ROLE OF GAS5 IN GC RESPONSE**





# ROLE OF GAS5 IN GC RESPONSE IN CHILDREN WITH IBD









# **ROLE OF GAS5 on NF-kB activity by EMSA**



NF-kB EMSA analyses in HeLa cells transfected with empty pcDNA3.1 (EMPTY CTRL) and pcDNA3.1\_GAS5 (GAS5 CTRL), after 4 (lanes 1, 2) and 24 h (lanes 3, 4) from transfection or treated with TNF- $\alpha$  (lane 5).



# **ROLE OF GAS5 on NF-kB activity by EMSA**



NF-kB EMSA analyses in HeLa cells transfected with empty pcDNA3.1 (EMPTY) and pcDNA3.1\_GAS5 (GAS5), treated with DEXA 100 nM (lanes A and B 3, 4) and 1  $\mu$ M (lanes A and B 5, 6) and untreated (CTRL; lanes A and B 1, 2) after 4 (A) or 24 h (B).





GC GR GR AR GAS-5 ΝFκB ΝϜκΒ

GAS5

Plasmid

+ **GC** 







Lucafò M. et al., Clin and Exp Pharm and Phys 2016